The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. Placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis in 160 randomised patients. Primary endpoints: Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo. Secondary endpoints are: Efficacy evaluation: Global impression of efficacy expressed by the patient and the physician (VAS), Grip strength (measured manometrically); Morning stiffness duration; Consumption of Paracetamol; Tolerability (4-point verbal scale); Adverse Events occurring during the treatment period; Other parameters:Treatment compliance; Biological markers of arthritis. Inclusion Criteria: - Patients of either sex - Aged 40 and over - Outpatients - Patients fulfilling the ACR criteria for the reporting of hand OA - Patients showing X-ray features of hand OA on at least two joints (2 IP and/or 1 IP and 1 TMC) of the dominant hand on standard plain radiographs ( or = 40 mm at inclusion time).

- Showing a FIHOA score > or = 6. - Having had at least two painful flares in a finger joint during the previous 12 month. - Patients who have signed the written informed consent for their participation in the study - Patients able to understand and follow the protocol. - Patients with a satisfying health and nutritional status. - Female subjects of childbearing potential using, within three months prior to the inclusion in the study, a reliable form of contraception during the course of the study (oral contraceptive pill, intrauterine device or condoms) or female of non childbearing potential (hysterectomy, bilateral ovariectomy or tubal section/ligation).

All VLC-1188-S control logic is programmed with Alerton’s easy-to-learn graphical programming language, VisualLogic®. This self-documenting software’s complete function library enables you to implement entirely flexible control strategies. A single VLC-1188-S can contain numerous. Visual logic software and help! Free visual logic manual downloads. Kepware's software solutions for the Industrial Automation Industry bridge the communication gap between diverse hardware and software applications. IMPORTANT - PURCHASE OF ALERTON PRODUCTS OR USE OF SOFTWARE, FIRMWARE AND / OR ACCOMPANYING DOCUMENTATION.! Alerton visual logic software. Leading Alerton’s Ascent product line, Compass is a powerful, dynamic interface enabling users to monitor and control their facilities from anywhere, at any time. Compass incorporates the latest browser technology and is truly the marriage of current technology and building automation.

Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand. The goal of the present study is to investigate the effectiveness of Condrosulf® 800.

- Female subjects of childbearing potential with a negative urinary pregnancy test before the inclusion in the study. In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety. In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely. In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.

The dietary supplements chondroitin and glucosamine, separately or in combination, have been widely used to treat the pain of osteoarthritis of the knee. But do they work? When I wrote about glucosamine and chondroitin and in the evidence was mostly negative. Some studies supported the combination of glucosamine and chondroitin, but many others didn’t; and there was little evidence that chondroitin alone had any effect. After reviewing all the published studies, the American Academy of Orthopaedic Surgeons.

Published in the BMJ Annals of the Rheumatic Diseases contradicts several previous studies: it found that chondroitin was effective, as effective as celecoxib, a non-steroidal anti-inflammatory drug (NSAID). A common objection when a dietary supplement fails testing is that they didn’t use the right dose or the right formulation. This reasoning might be valid, but it could easily lead to an unending and unproductive proliferation of studies each using slightly different regimens. This new study avoided that objection by using the dose and the specific formulation that had been shown effective in the most positive studies. Previous studies of chondroitin had suffered from idiosyncratic trial design. Obrazec zhaloba na otsutstvie ulichnogo osvescheniya. This new study followed the guidelines of the European Medicines Agency: • a minimum 6-month study • a three-arm design including a placebo and an active comparator (i.e.